What other drugs are available after ixazomib resistance?

Ixazomib and bortezomib are two important proteasome inhibitors that are widely used in the treatment of hematological malignancies such as multiple myeloma. However, as treatment progresses, some patients may develop resistance to ixazomib, and other effective treatments need to be found.

When resistance to ixazomib occurs, bortezomib often becomes an important alternative. Although these two drugs have similar mechanisms of action and both inhibit the growth and spread of cancer cells by inhibiting the proteasome, there are certain differences in their chemical structures and clinical properties. Therefore, even if patients become resistant to ixazomib, bortezomib may still have a good therapeutic effect.

In addition to bortezomib, daratumumab and carfilzomib are also important drugs in the treatment of multiple myeloma, especially after patients develop resistance to other drugs. Daratumumab is a monoclonal antibody that targets CD38 and can induce tumor cell death through multiple mechanisms. Carfilzomib is a new proteasome inhibitor that has stronger proteasome inhibitory activity and lower neurotoxicity than bortezomib and ixazomib.

When choosing alternative drugs, doctors will make comprehensive considerations based on the patient's specific situation, the severity of the disease, and the drug's toxic and side effects. At the same time, with the continuous deepening of medical research, more new and efficient therapeutic drugs may appear in the future, providing more treatment options for patients with multiple myeloma.

In addition, for patients with ixazomib resistance, in addition to drug treatment, diversified treatment methods such as combination treatment options, individualized treatment strategies, and participation in clinical trials can also be considered. These modalities help patients better control their condition, reduce symptoms, and improve quality of life.

In short, resistance to ixazomib does not mean the end of treatment. With the guidance and help of a doctor, it is still possible for patients to find effective treatment drugs and programs that suit them.